Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You are a man or a woman
- You are covered by a social security or health insurance system
- You are having a specific type of stem cell transplant (using stem cells from the blood, not from umbilical cord blood) from a donor, for a blood cancer that is currently under control
- You have read, understood, and signed a consent form agreeing to take part
Who may not be able to join:
- Your blood cancer is currently getting worse or spreading at the time of the transplant
- You have difficulty understanding the study, for example due to a language barrier or cognitive difficulties
- You have a history of another active cancer, or had one in the last 3 years (a common type of skin cancer called basal cell carcinoma is not counted)
- You have another serious illness that is not well controlled, such as severe heart, kidney, liver, or breathing problems, or a severe infection
- You have problems controlling your bowel movements (fecal incontinence)
- You are already taking part in another clinical trial that involves the transplant process, the drugs used to prevent rejection, treatment or prevention of a transplant complication called GvHD, or another trial testing a gut bacteria transplant (FMT) (confirm with trial site)
- You are pregnant
- You are under legal guardianship or a court-ordered protection arrangement
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jacques-Olivier BAY, MD, PhD, University Hospital, Clermont-Ferrand
Phone: +33473754963
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Graft-versus-host disease and Relapse-Free Survival (GRFS) rate after allogeneic hematopoietic stem cell transplantation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.